DDrare: Database of Drug Development for Rare Diseases

210. 単心室症
［臨床試験数：47，薬物数：54（DrugBank：23），標的遺伝子数：32，標的パスウェイ数：66］

Searched query = "Single Ventricle", "SV", "Single ventricle heart defect", "Univentricular heart", "UVH", "Single ventricular circulation syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACETYLSALICYLIC ACID; ACT-064992; Acetylsalicylic acid; Administration of an ACE-inhibitor or not; Aesculus Hippocastanum / Horse Chestnut; Ambrisentan; Arginine; Aspirin; Autologous Tissue-Engineered Vascular Graft; BAY 59-7939; Bosentan; Carvedilol; Colchicine; Digoxin; Enalapril; Eplerenone; Horse chestnut; JNJ-39039039; Liothyronine; Liothyronine I 131; MACITENTAN; MPC; MZ101; Macitentan; Milk; Mysildecard; Mysildecard 20 mg; Nitric Oxide; Normal Saline; ODSH at 0.125 mg/kg/h; ODSH at 0.250 mg/kg/h; ODSH at 0.375 mg/kg/h; Opsumit; Opsumit®; Other: Human Milk Derived Fortifier; Other: Human/Bovine Milk; RIVAROXABAN; Rexlemestrocel-L; Rivaroxaban; SCRM001_TEVG; Sildenafil; Sildenafil by injection; Spironolactone; Spironolactone (drug); Sugar pill; Tadalafil; Tadalafil Citrate; Tracleer; Treprostinil; Udenafil; Vasopressin; Vasopressin, Arginine; Vitamin C; Xarelto

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03088345 (ClinicalTrials.gov)	March 6, 2017	28/2/2017	Early Use of Vasopressin in Post-Fontan Management	Use of Arginine Vasopressin in Early Postoperative Management After Fontan Palliation	Circulatory Perfusion Disorder;Congenital Heart Disease;Single-ventricle	Drug: Vasopressin , Arginine;Drug: Placebo	Medical College of Wisconsin	NULL	Completed	N/A	18 Years	All	20	Phase 2;Phase 3	United States
2	NCT02975999 (ClinicalTrials.gov)	December 2016	22/9/2016	Use of Vasopressin Following the Fontan Operation	Use of Vasopressin Following the Fontan Operation: Both Pilot and Multicenter Studies	Pleural Effusion;Single-ventricle	Drug: Vasopressin;Drug: Normal Saline	Advocate Health Care	NULL	Suspended	18 Months	7 Years	All	84	Phase 2;Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03088345
(ClinicalTrials.gov)

March 6, 2017

28/2/2017

Early Use of Vasopressin in Post-Fontan Management

Use of Arginine Vasopressin in Early Postoperative Management After Fontan Palliation

Circulatory Perfusion Disorder;Congenital Heart Disease;Single-ventricle

Drug: Vasopressin , Arginine;Drug: Placebo

Medical College of Wisconsin

NULL

Completed

N/A

18 Years

All

Phase 2;Phase 3

United States

NCT02975999
(ClinicalTrials.gov)

December 2016

22/9/2016

Use of Vasopressin Following the Fontan Operation

Use of Vasopressin Following the Fontan Operation: Both Pilot and Multicenter Studies

Pleural Effusion;Single-ventricle

Drug: Vasopressin;Drug: Normal Saline

Advocate Health Care

NULL

Suspended

18 Months

7 Years

All

Phase 2;Phase 3

United States